Oncotarget

Case Reports:

Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression

Gregorio J. Petrirena _, Julien Masliah-Planchon, Quentin Sala, Bertrand Pourroy, Didier Frappaz, Emeline Tabouret, Thomas Graillon, Jean-Claude Gentet, Olivier Delattre, Olivier Chinot and Laetitia Padovani

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:10175-10183. https://doi.org/10.18632/oncotarget.23699

Metrics: PDF 2358 views  |   HTML 2584 views  |   ?  


Abstract

Gregorio J. Petrirena1, Julien Masliah-Planchon2,3, Quentin Sala4, Bertrand Pourroy5, Didier Frappaz6, Emeline Tabouret1,7, Thomas Graillon8, Jean-Claude Gentet9, Olivier Delattre2,3, Olivier Chinot1,7 and Laetitia Padovani10

1Service de Neuro-Oncologie, Hôpital La Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France

2Unité de Génétique Somatique, Département de Génétique Oncologique, Institut Curie, Paris, France

3INSERM_U830, Institut Curie, Paris, France

4Service de Médecine Nucléaire, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille, Marseille, France

5Unité Oncopharma, Service Pharmacie, Hôpital La Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France

6Service de Neuro-Oncologie Pédiatrique et Adulte, Centre Léon Bérard, Lyon, France

7Aix-Marseille Université, Marseille, France

8Service de Neurochirurgie, Hôpital La Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France

9Service d’Oncologie et Hématologie Pédiatrique, Hôpital La Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France

10Service de Radiothérapie, Hôpital La Timone, Assistance Publique-Hôpitaux de Marseille, Marseille, France

Correspondence to:

Gregorio J. Petrirena, email: [email protected]

Keywords: sonic hedgehog medulloblastoma; vismodegib; temozolomide; smoothened mutation; PIK3CA mutation

Received: June 03, 2017     Accepted: November 01, 2017     Published: January 03, 2018

ABSTRACT

Background: Response to targeting and non-targeting agents is variable and molecular information remains poorly described in patients with recurrent sonic-hedgehog-driven medulloblastoma (SHH-MB).

Materials and Methods: Clinical and PET/CT findings during treatment with successive hedgehog antagonists and temozolomide monotherapies are described in a heavily pre-treated patient with recurrent extraneural metastases from PTCH1 mutated/ wild type smoothened (SMO) CNS SHH-MB. Molecular tests were prospectively performed in tissue from two extraneural sites at progression.

Results: Sustained clinical/metabolic response was obtained to vismodegib. At progression, itraconazole was ineffective, but salvage temozolomide treatment results in a response similar to vismodegib. At further progression, acquired SMO and PIK3CA mutations were identified in bone (G477L and H1047A, respectively) and epidural (L412P and H1065L, respectively) metastases. No response was observed with subsequent sonidegib treatment.

Conclusions: This is the first clinical report of recurrent extraneural PTCH1 mutated SHH-MB exhibiting: 1) a sustained response to vismodegib and temozolomide, and 2) inter-metastatic molecular heterogeneity and acquired SMO-G477L, SMO-L412P, and PIK3CA-H1065L mutations at progression, highlighting the need for a multitarget treatment approach.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23699